je.st
news
Tag: of
Demolition will clear the way for new student housing at University of Louisville
2015-05-29 20:42:00| American School & University
$45 million facility will provide living space for 500 students. read more
Tags: of
clear
university
student
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
2015-05-29 20:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, a well-established form of genetic instability in many cancers characterized by the loss of function of the MMR pathway. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
The ABCs (and CDK and M's) of Bone Health
2015-05-29 15:38:00| Food Processing
Mushrooms and UV-treated bakers yeast can be significant non-animal sources of vitamin D.
W&T Offshore announces first production from SS #6 well in Gulf of Mexico
2015-05-29 01:00:00| Offshore Technology
W&T Offshore has announced a new discovery at Ewing Banks 910 and first production from the SS #6 well at Mississippi Canyon 538 field (Medusa) located in the deepwater of the Gulf of Mexico.
Tags: of
well
production
mexico
Genelux announces promising data from two phase I trials of GL-ONC1...
2015-05-28 22:50:38| Logistics - Topix.net
Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that data from two Phase I trials evaluating its lead oncolytic virotherapy GL-ONC1 in head and neck cancer and malignant pleural mesothelioma demonstrate a favorable safety profile and support further investigation of the therapy in both indications. The results will be presented by lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center at the upcoming 2015 American Society of Clinical Oncology Annual Meeting, being held May 29-June 2 in Chicago, IL.
Sites : [628] [629] [630] [631] [632] [633] [634] [635] [636] [637] [638] [639] [640] [641] [642] [643] [644] [645] [646] [647] next »